India, Aug. 12 -- Maze Therapeutics, Inc. (MAZE) a clinical-stage biotech company, announced financial results for the second quarter, highlighting wider loss than a year ago, driven by higher operating expenses.
Company Profile
Maze is focused on developing small-molecule precision medicines for kidney and metabolic diseases. The company uses its proprietary Maze Compass platform to identify genetically validated disease targets.
Its lead pipeline includes MZE829, an APOL1 inhibitor for APOL1-mediated kidney disease, and MZE782, an SLC6A19 inhibitor being developed for phenylketonuria and chronic kidney disease.
Pipeline Update
MZE829 for APOL1-Mediated Kidney Disease (AMKD)
Maze's oral APOL1 inhibitor MZE829 is being evaluated in th...